Pro Athletes Team Up to Champion Gout Awareness

               Pro Athletes Team Up to Champion Gout Awareness

Emmitt Smith Joins Professional Basketball, Baseball and Racing Stars in
Partnering with Takeda on Gout Education Campaign

PR Newswire

DEERFIELD, Ill., July 9, 2013

DEERFIELD, Ill., July 9, 2013 /PRNewswire/ -- For Emmitt Smith, Pro Football
running back legend, as an athlete, pain was a part of the job. Yet he
describes a gout flare as a level of pain like nothing else he had felt
before. Along with an estimated 8 million Americans, Smith suffers from gout,
a serious form of arthritis, and he's joining a team of sports stars to share
his gout story. Together, they are partnering with Takeda Pharmaceuticals
U.S.A., Inc. (Takeda) on the "Champions for Gout Awareness" educational
campaign, highlighting the importance of managing the pain of acute gout and
the underlying chronic condition in gout patients with hyperuricemia.

"My gout attack was like a defensive linebacker I never saw coming. The pain
and diagnosis surprised me," says Smith. "I had a lot of misconceptions about
gout. I thought it was an 'old man's disease', and I thought I could power
through the pain on my own. Now I know it's the most common form of
inflammatory arthritis in men over the age of 40, and that I have to work with
my doctor to help manage my gout."

Basketball star Alonzo Mourning, pitching great David Wells and stock car
racing crew chief Kevin "Bono" Manion – champions in their own sports – are
joining Smith in the common goal of connecting with people to reinforce the
importance of the patient/doctor partnership in more actively managing the
disease. As experts in their sports and gout patients, over the coming months,
these champions will share their perspective on key sports moments, as well as
what they've experienced and learned about this form of arthritis.

"Like these influential sports figures, many of my patients are surprised by
the pain and diagnosis of gout. Gout is a chronic, progressive condition, that
may get worse over time," says Theodore Fields, M.D., F.A.C.P., director of
the Rheumatology Faculty Practice Plan at the Hospital for Special Surgery in
New York City. "Many gout patients suffer from the painful symptoms of acute
gout, commonly known as flares, and the underlying chronic condition, which is
a buildup of uric acid called hyperuricemia. Whether it is treating and
managing gout flares or lowering uric acid levels, I encourage patients to
take an active role in their treatment and to talk openly and often with their
doctor about their gout."

Gout is a crystal-induced arthritis. While gout is more common in men, women
also can suffer from gout and are most often affected after menopause. Gout
flares are characterized by intense pain, redness, swelling and heat in the
affected joints, most commonly in the big toe, caused by a buildup of uric
acid. According to the 2012 American College of Rheumatology Guidelines for
managing gout, a goal in treatment of gout is to reduce the uric acid level in
the blood to below 6 mg/dL. Excessive uric acid may lead to crystals forming
and building up in joints, possibly leading to joint damage over time. Gout
may be managed through diet and lifestyle changes along with medications, as
needed, to treat and reduce the risk of gout flares and lower uric acid

"Champions for Gout Awareness gives me the chance to share my gout experience.
For me, it's about educating myself about gout and working closely with my
doctor. I hope Alonzo, David, Kevin and I can inspire others who live with
gout to learn as much as they can about the condition and, most importantly,
to work closely with their doctors to manage gout flares as well as working to
target healthy uric acid levels," notes Smith.

About the Takeda Gout Franchise
Takeda is committed to making a stronger impact on gout treatment through
ongoing research, greater scientific insights and education and support for
physicians and patients. Takeda provides multiple therapeutic options for gout
patients including Colcrys (colchicine, USP) for the treatment and prevention
of flares associated with gout and Uloric (febuxostat), used to lower blood
uric acid levels in adults with gout. To help make gout treatment more
affordable and accessible, Takeda offers patient assistance programs and other
robust savings programs and resources to address patient needs and help ensure
access to Takeda medicines. To learn more about Takeda's patient assistance
program, please visit or call 1-800-830-9159.

About Colcrys
Colcrys (colchicine, USP) is a prescription medicine used in adults for the
treatment of flares associated with gout when taken at the first sign of a
flare, as well as prevention of flares. Colcrys is not a pain medicine and it
should not be taken to treat pain from other causes. Colcrys is a trademark of
Takeda Pharmaceuticals U.S.A., Inc. registered with the U.S. Patent and
Trademark Office and used under license by Takeda Pharmaceuticals America,
Inc. For more information about Colcrys including patient savings programs,

Important Safety Information for Colcrys

  oColcrys can cause serious side effects or death if levels of Colcrys are
    too high in your body. Taking certain medicines with Colcrys can cause
    your level of Colcrys to be too high, even at recommended doses,
    especially if you have kidney or liver problems.
  oTell your healthcare provider about all your medical conditions and all
    the medicines you take, including prescription and non-prescription
    medicines, vitamins, and herbal supplements, and if you consume grapefruit
  oFatal overdoses, both accidental and intentional, have been reported in
    adults and children who have ingested colchicine. Keep Colcrys out of the
    reach of children.
  oColcrys can also cause serious muscle problems and blood disorders even
    when taken as directed. You have a higher chance for muscle problems if
    you are elderly, are taking certain other medicines with Colcrys, or have
    kidney problems.
  oTell your healthcare provider if you have any side effect that bothers you
    or that does not go away.
  oThe most common side effects in people who have gout flares are diarrhea
    (23%) and throat pain (3%).

For further information, please talk to your healthcare provider and see the
complete Prescribing Information and Medication Guidefor Colcrys.

About Uloric
Uloric (febuxostat) is a prescription medicine used to lower blood uric acid
levels in adults with gout. Uloric is not for the treatment of high uric acid
without a history of gout. Uloric is a registered trademark of Teijin Pharma
Limited and used under license by Takeda Pharmaceuticals U.S.A., Inc. For more
information about Uloric including patient savings programs, visit

Important Safety Information for Uloric

  oDo not take Uloric if you are taking Azathioprine or Mercaptopurine.
  oYour gout may flare up when you start taking Uloric; do not stop taking
    your Uloric even if you have a flare. Your healthcare provider may give
    you other medicines to help prevent your gout flares.
  oA small number of heart attacks, strokes, and heart-related deaths were
    seen in clinical studies. It is not certain that Uloric caused these
  oTell your healthcare professional about liver or kidney problems or a
    history of heart disease or stroke.
  oYour healthcare professional may do blood tests to check your liver
    function while you are taking Uloric.
  oThe most common side effects of Uloric are liver problems, nausea, gout
    flares, joint pain, and rash.

Please see the complete Prescribing Informationand talk to your healthcare

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit, or call 1-800-FDA-1088.

Takeda Pharmaceuticals U.S.A., Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals U.S.A., Inc. is a subsidiary
of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company
in Japan. The respective companies currently market oral diabetes, insomnia,
rheumatology, and gastroenterology and cardiovascular treatments and seek to
bring innovative products to patients through a pipeline that includes
compounds in development for metabolic and cardiovascular disease,
gastroenterology, neurology and other conditions. To learn more about these
Takeda companies, visit

SOURCE Takeda Pharmaceuticals U.S.A., Inc.

Contact: Jessica Tuquero, Takeda Pharmaceuticals U.S.A., Inc., 224-554-2021,; Carrie Rose, Ketchum, 646-935-3938,
Press spacebar to pause and continue. Press esc to stop.